LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

MacroGenics Inc

Închisă

SectorSănătate

1.57 2.61

Rezumat

Modificarea prețului

24h

Curent

Minim

1.48

Maxim

1.61

Indicatori cheie

By Trading Economics

Venit

-72M

-15M

Vânzări

-93M

18M

P/E

Medie Sector

38.83

56.602

EPS

-0.818

Marjă de profit

-86.977

Angajați

341

EBITDA

-71M

-12M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+192.21% upside

Dividende

By Dow Jones

Următoarele câștiguri

4 aug. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

-87M

100M

Deschiderea anterioară

-1.04

Închiderea anterioară

1.57

Sentimentul știrilor

By Acuity

15%

85%

18 / 382 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

MacroGenics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

16 mai 2025, 19:39 UTC

Principalele dinamici ale pieței

UroGen Falls to 52-Week Low, FDA Document Indicates Cancer Drug Study Disagreement

16 mai 2025, 23:18 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- 2nd Update

16 mai 2025, 22:30 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- Update

16 mai 2025, 21:56 UTC

Market Talk

Fitch Raises Greece's Outlook to Positive From Stable -- Market Talk

16 mai 2025, 21:56 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

16 mai 2025, 21:54 UTC

Top știri

U.S. Loses Last Triple-A Credit Rating -- WSJ

16 mai 2025, 21:22 UTC

Market Talk

Moody's Says U.S. Fiscal Performance Likely to Deteriorate -- Market Talk

16 mai 2025, 21:17 UTC

Market Talk

Treasury Yields Rise, Dollar Falls After Moody's Cuts U.S. Credit Rating -- Market Talk

16 mai 2025, 21:17 UTC

Top știri

The Score: UnitedHealth, Walmart, Coinbase Global and More Stocks That Moved on the Week's News -- WSJ

16 mai 2025, 21:05 UTC

Market Talk

Moody's Downgrades U.S. Credit Rating Due to Deficit, Debts -- Market Talk

16 mai 2025, 20:55 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 20:50 UTC

Market Talk
Câștiguri

Financial Services Roundup: Market Talk

16 mai 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

16 mai 2025, 20:37 UTC

Top știri

Trade Progress Sparks Bullish Week for Wall Street -- WSJ

16 mai 2025, 20:33 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Dick's-Foot Locker Deal Looks Like a Bet on Nike's Turnaround -- Market Talk

16 mai 2025, 20:30 UTC

Achiziții, Fuziuni, Preluări

Galaxy Digital Begins U.S. Trading as Bitcoin Keeps Powering Ahead -- Barrons.com

16 mai 2025, 20:18 UTC

Top știri

Major U.S. Stock Indexes Rise; U.S. Running Out of Patience for Trade Deals -- WSJ

16 mai 2025, 20:16 UTC

Top știri

Justice Department Wants to Spare Boeing From Guilty Plea Over 737 MAX Charges -- 3rd Update

16 mai 2025, 20:15 UTC

Câștiguri

Tesla Stock Rises. Even Hedge Fund Sales Can't Keep It Down. -- Barrons.com

16 mai 2025, 20:11 UTC

Achiziții, Fuziuni, Preluări

Henry Schein: William K. Daniel Joins Board

16 mai 2025, 20:10 UTC

Achiziții, Fuziuni, Preluări

Henry Schein: Strategic Investment by KKR Completed

16 mai 2025, 20:05 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 19:38 UTC

Market Talk

Oil Futures Post Second Straight Weekly Gain -- Market Talk

16 mai 2025, 19:07 UTC

Market Talk

U.S. Natural Gas Futures End Week Lower -- Market Talk

16 mai 2025, 18:51 UTC

Top știri

Early Read on Consumer Sentiment Falls to Second Lowest on Record -- 5th Update

16 mai 2025, 18:41 UTC

Achiziții, Fuziuni, Preluări

What's Next for Cable Giant Comcast After Charter-Cox Merger -- Barrons.com

16 mai 2025, 18:37 UTC

Market Talk

Gold Futures End Week on Negative Note -- Market Talk

16 mai 2025, 18:35 UTC

Top știri

Ozempic Drugmaker's CEO Pushed Out Amid Weight-Loss Market Challenges -- 3rd Update

16 mai 2025, 18:32 UTC

Top știri

Trump Floats Plan to Impose New Tariff Rates; Stocks Hold Steady -- WSJ

16 mai 2025, 18:28 UTC

Market Talk

Weaker Dollar Seen as Helping Some Business to Avoid Price Increases -- Market Talk

Comparație

Modificare preț

MacroGenics Inc Așteptări

Obiectiv de preț

By TipRanks

192.21% sus

Prognoză pe 12 luni

Medie 4.5 USD  192.21%

Maxim 8 USD

Minim 2 USD

În baza a 7 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruMacroGenics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

7 ratings

2

Cumpărare

5

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

1.47 / 1.64Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Bullish Evidence

Termen lung

Bearish Evidence

Sentiment

By Acuity

18 / 382 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.